Organisation paid for research Program year 2025 Source: CMS Open Payments

WCG Clinical

Neither a doctor nor a teaching hospital

Research payments

$449,866

54 payments

Through program year 2025, WCG Clinical is reported as receiving $449,866 in research payments, across 54 payments.

By program year

2 rows

Year	Kind	Amount	Payments
2025	Research	$352,661	7
2024	Research	$97,206	47

Breakdown

Who paid Research payments · program years 2024–2025

AstraZeneca Pharmaceuticals LP $331,494 2 payments
GlaxoSmithKline, LLC. $58,789 11 payments
Provepharm Inc. $47,702 38 payments
Celgene Corporation $9,836 2 payments
Ucb SA $2,046 1 payment

Studies the money was for Research payments · program years 2024–2025

Anchor $331,494 2 payments
A 52-Week, Randomised, Double-Blind, Double-Dummy, Parallel Group, Mul $38,994 5 payments
Pvp-22Ic04 $23,498 17 payments
Pvp-22Ic05 $22,725 20 payments
A Phase 3A, Observer-Blind, Randomized, Controlled Study to Demonstrat $15,521 3 payments
Phase 1 Drug Interaction (AKA IM042-002) (CC-93538-DDI-001) (EOE) $6,236 1 payment
A Phase II, Single-Blind, Randomized, Controlled Study to Evaluate the $4,274 3 payments
A Phase 1, open-label, single-sequence study to evaluate potential disease-mediated drug-drug interaction with selected cytochrome P450 substrates in adult subjects with active eosinophilic esophagitis receiving cendakimab $3,600 1 payment
A Double-Blind, Randomized, Placebo-Controlled, Multicenter, Outpatient, Parallel-Group Study to Assess the Efficacy and Safety of Staccato Alprazolam in Study Participants 12 Years of Age and Older With Stereotypical Prolonged Seizures $2,046 1 payment
Pvp-24Bd01 $1,479 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.